New PLUS” trial version includes third gene target for rapid detection of future SARS-CoV-2 variants
Sunnyvale, Calif., May 19, 2022 /PRNewswire/ — Cepheid announced today that it has received the Xpert . CE Mark approved forexpress cov-2plus A rapid diagnostic PCR test has been received for qualitative identification of SARS-CoV-2 virus, the causative agent of COVID-19.
Viruses are constantly changing through mutation, and can generate new types with unique characteristics. During pandemics, several forms of the virus that cause COVID-19 have been documented around the world. Cepheid actively addresses this increasing genetic diversity by improving gene coverage of new ones plus- version of the test and includes a third conserved gene target for SARS-CoV-2 detection to address the challenge of future virus mutation and to adapt the nucleocapsid gene probe for persistent virus detection.
specialist express cov-2plus Connects to Xpert, among othersexpress COV-2/Flu/RSV plus Cepheid’s growing range of PCR productsplus Respiratory PCR tests that provide fast, accurate and actionable results. specialistexpress COV-2/Flu/RSV plusThe most suitable product remains the same even when multiple viruses that cause influenza-like illness are in circulation. specialistexpress cov2 plusIt is now approved for use on all patients who are being evaluated or suspected of having COVID-19 without any symptoms.
specialist express cov-2 plusFor use on any of the more than 40,000 GeneXperts in use worldwideSystems designed by Cepheid. test SARS-CoV-2 can rapidly detect RNA in as little as 20 minutes if necessary for positive results.1
Right from the start of the pandemic, our focus was on staying ahead of SARS-CoV-2 gene drift, and so we designed our tests with current and potential future variants in mind,” commented. David Pershing, MD, PhD, EVP and Chief Scientific Officer. The high sensitivity of these tests is now particularly relevant to the recently announced trial-to-treatment initiative, as early detection is of paramount importance to achieve optimal clinical outcome with antiviral therapy.”
Xpert. delivery of express cov-2 plus Expected to start in May.
For more information, including video and package inserts, visit www.cepheid.com/coronavirus,
Cepheid. About this
Based in Sunnyvale, California, Cepheid is a leader in molecular diagnostics. Cepheid aims to improve healthcare through the development, manufacturing and commercialization of precise yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual processes, Cepheid’s solutions enable institutions of all sizes to conduct complex molecular diagnostic tests on organ and genetic diseases. With its extensive molecular biology capabilities, the company focuses on applications where the most accurate, rapid and actionable test results are required, such as the treatment of infectious diseases and cancer. for more information please visit http://www.cepheid.com/de,
For inquiries from Cepheid Media:
door peterson
[email protected]
Web guru. Amateur thinker. Unapologetic problem solver. Zombie expert. Hipster-friendly travel geek. Social mediaholic.
